Drug name - Namzaric

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8598233 ALLERGAN Method for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8173708 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8362085 ALLERGAN Method for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8338486 ALLERGAN Methods for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8283379 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8580858 ALLERGAN Compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8329752 ALLERGAN Composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8168209 ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject Nov, 2025

(3 years from now)

US8293794 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8338485 ALLERGAN Compositions for the treatment of CNS-related conditions Nov, 2025

(3 years from now)

US8329752

(Pediatric)

ALLERGAN Composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8283379

(Pediatric)

ALLERGAN Methods and compositions for the treatment of CNS-related conditions May, 2026

(3 years from now)

US8173708

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8362085

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8598233

(Pediatric)

ALLERGAN Method for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8168209

(Pediatric)

ALLERGAN Method and composition for administering an NMDA receptor antagonist to a subject May, 2026

(3 years from now)

US8039009 ALLERGAN Modified release formulations of memantine oral dosage forms Mar, 2029

(6 years from now)

US8039009

(Pediatric)

ALLERGAN Modified release formulations of memantine oral dosage forms Sep, 2029

(6 years from now)

US8058291 ALLERGAN Methods and compositions for the treatment of CNS-related conditions Dec, 2029

(7 years from now)

Drugs and Companies using DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE ingredient

Treatment: Memantine hcl/donepezil hcl combination for the treatment of moderate to severe dementia of the alzheimer's type

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;7MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;14MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;21MG CAPSULE, EXTENDED RELEASE;ORAL Prescription
10MG;28MG CAPSULE, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.